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Abstract: Objective: Recent studies reported a signal intensity increase in the deep cerebellar nuclei
(DCN) on magnetic resonance images caused by gadolinium deposition after the injection of gadolinium-
based contrast agents (GBCAs). There is an ongoing debate if the propensity of a GBCAto deposit
gadolinium is primarily determined by its class as either linear or macrocyclic. In the current study, we
aimed to compare the amount and the distribution of retained gadolinium of linear and macrocyclic GB-
CAs in the DCN after a single injection at a dose comparable to a human patient’s in a large animal model.
Materials and Methods: Eighteen sheep were randomly assigned in 6 groups of 3 animals, which received
a single injection of 0.1 mmol/kg body weight of either the macrocyclic GBCAs gadobutrol, gadoteridol,
or gadoterate meglumine; the linear GBCAs gadobenate dimeglumine or gadodiamide; or saline. Animals
were euthanized 10 weeks after injection. Local distribution and concentration of gadolinium and colocal-
ization to other metals (iron, zinc, copper) in the DCN was assessed by laser ablation-inductively coupled
plasma-mass spectrometry. Results: Average gadolinium concentration for the macrocyclic GBCAs and
the saline groupwas below the limit of quantification (5.7 ng/g tissue). In contrast, 14 (for gadobenate)
and 27 (for gadodiamide) times more gadolinium than the limit of quantification was found for the linear
GBCAs gadobenate (mean, 83 ng/g) or gadodiamide (mean, 155 ng/g brain tissue). Gadolinium dis-
tribution colocalized with other metals for linear GBCAs and a specific accumulation in the DCN was
found. Discussion: The current study supports the hypothesis that the amount of gadolinium deposited
in the brain is primarily determined by its class as either macrocyclic or linear. The accumulation of
gadolinium in the DCN for linear GBCAs explains the hyperintensities in the DCN found in previous
patient studies with linear GBCAs.
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Objective:Recent studies reported a signal intensity increase in the deep cerebel-
lar nuclei (DCN) on magnetic resonance images caused by gadolinium deposi-
tion after the injection of gadolinium-based contrast agents (GBCAs). There is
an ongoing debate if the propensity of a GBCA to deposit gadolinium is primarily
determined by its class as either linear or macrocyclic. In the current study, we
aimed to compare the amount and the distribution of retained gadolinium of
linear and macrocyclic GBCAs in the DCN after a single injection at a dose
comparable to a human patient's in a large animal model.
Materials andMethods: Eighteen sheep were randomly assigned in 6 groups
of 3 animals, which received a single injection of 0.1 mmol/kg body weight of
either the macrocyclic GBCAs gadobutrol, gadoteridol, or gadoterate meglumine;
the linear GBCAs gadobenate dimeglumine or gadodiamide; or saline. Animals
were euthanized 10 weeks after injection. Local distribution and concentration of
gadolinium and colocalization to other metals (iron, zinc, copper) in the DCN
was assessed by laser ablation-inductively coupled plasma-mass spectrometry.
Results: Average gadolinium concentration for the macrocyclic GBCAs and the
saline groupwas below the limit of quantification (5.7 ng/g tissue). In contrast, 14
(for gadobenate) and 27 (for gadodiamide) times more gadolinium than the limit
of quantification was found for the linear GBCAs gadobenate (mean, 83 ng/g) or
gadodiamide (mean, 155 ng/g brain tissue). Gadolinium distribution colocalized
with other metals for linear GBCAs and a specific accumulation in the DCN
was found.
Discussion: The current study supports the hypothesis that the amount of
gadolinium deposited in the brain is primarily determined by its class as either
macrocyclic or linear. The accumulation of gadolinium in the DCN for linear
GBCAs explains the hyperintensities in the DCN found in previous patient studies
with linear GBCAs.
Key Words: GBCA, gadolinium-based contrast agents, macrocyclic GBCAs,
linear GBCAs
(Invest Radiol 2019;54: 531–536)
I n the last 4 years, the debate on the deposition of gadolinium inpatient's brains after serial injections of gadolinium based contrast
agents (GBCAs) has been among the top issues debated in radiological
science.1 The debate started at the beginning of 2014 when Tomonori
Kanda reported for the first time increasing hyperintensities on
nonenhanced T1-weighted magnetic resonance imaging (MRI) scans
in the dentate nucleus (DN) and the globus pallidus that correlated with
the number of previous GBCA injections.2 Further research showed that
gadolinium stored in the brain tissue was the source of the hyperintensities
and that also other parts of the brain were affected with the DN showing
the highest amounts of gadolinium.3–5 Subsequent studies reported that
hyperintensities in the DN were exclusively found after the injection of
linear GBCAs, but not after injection of macrocyclic GBCAs.6,7 Ever
since, a multitude of preclinical and clinical studies has been published
assessing the propensity of the marketed GBCAs to cause hyperintensities
or gadolinium deposition in the brain or other parts of the body.1,5–18
The intensive scientific debate on gadolinium depositions culminated
in 2017 with divergent regulatory actions. Although the European Union
decided to remove all linear GBCAs (with a few minor exceptions) from
the market using a “precautionary approach,” the Food and Drug Admin-
istration issued a class warning for all marketed GBCAs.
The different propensity of linear and macrocyclic GBCAs to
cause hyperintensities has been debated in more than 50 research arti-
cles in the last 4 years.1,6–17 Although the majority of articles reported
no signal intensity increase after macrocyclic GBCA injections, some
positive findings19 kept the debate alive if macrocyclic GBCAs can
principally cause gadolinium accumulation in the DCN that finally be-
comes visible on MRI scans.
In the current study, we aimed to assess the concentration of
gadolinium retained in the DCN in a large animal model 10 weeks after
a single injection of the 3 marketed macrocyclic GBCAs gadobutrol,
gadoterate meglumine, and gadoteridol; the nonionic linear GBCA
gadodiamide; and the ionic linear GBCA gadobenate. Moreover, we
used laser ablation-inductively coupled plasma-mass spectrometry
(LA-ICP-MS) to investigate if an accumulation of gadolinium can be
identified in the DCN, which could explain the observed signal intensity
increase that was reported on nonenhanced T1-weighted MRI scans.
MATERIALS AND METHODS
The study was conducted as an “add-on” study to an already on-
going study on teeth abrasion of sheep depending on the provided food.
The study design followed the 3R requirements (replace, reduce, refine)
and was in accordance with the ethical obligation to maximize knowl-
edge that can be obtained from animal experiments. The study was con-
ducted according to Swiss animal welfare act and approved by the local
governmental authorities with the animal license number ZH235/17.
Eighteen female Swiss-Alpine sheep with an age between 4 and
10 years and with a body weight of 80.8 ± 19.6 kg were randomly
assigned (independent of age and body weight) to 1 of 6 groups with
3 animals each. The 5 treatment groups received an injection of one of
the following GBCAs at 0.1 mmol/kg (standard dose, based upon body
surface area normalization): Omniscan (gadodiamide, Omniscan; GE
Healthcare AG, Wädenswil, Switzerland), Multihance (gadobenate-
dimeglumine, MultiHance; Bracco Imaging Deutschland GmbH,
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Konstanz, Germany), Gadovist (gadobutrol, Gadovist; BayerVital GmbH,
Leverkusen, Germany), Prohance (gadoteridol, ProHance; Bracco Imaging
Deutschland GmbH, Konstanz, Germany), and Dotarem (gadoterate
meglumine, Dotarem; Guerbet AG, Paris, France). The control group
was injected with the equal volume of saline (0.2 mL/kg NaCl 0.9%;
B. Braun Medical AG; Sempach, Switzerland).
The person performing the injections was blinded to the treatment
groups as the syringes were randomly prepared by 2 persons unrelated to
the study. All injections were done under manual restraint at the vena
jugularis externa using an intravenous cathether (Surflo ETFE IV Catheter
18 gague  2″ [Green], reference number SR-OX1851CA; Terumo
Medical Corporate Office, New Jersey), which was removed directly
after the injection. No clinical abnormalities were detected in the study
cohort until termination of the experiment. The scientists who conducted
the LA-ICP-MS and the gadolinium quantification were blinded to the
GBCAs at all parts of the study.
Euthanization, Tissue Harvesting, and
Sample Preparation
Ten weeks after the initial injections, the animals were anesthe-
tized with 0.5 mg/kg body weight xylazine (xylazinum, Xylazin Streuli
ad us vet; Streuli Pharma AG, Uznach, Switzerland) and 5 mg/kg body
weight ketamine (Ketanarkon 100 ad us vet; Streuli Pharma AG) intra-
muscularly and euthanized with 100 to 150 mg/kg body weight pento-
barbital (pentobarbitalum natricum, Esconarkon ad us vet; Streuli
Pharma AG; 100–150 mg/kg body weight) intravenously. The death
of the animals was confirmed by the reversal of the heartbeat and the
pupillary reflex, and all tissues were harvested immediately thereafter.
The brain was excised in total and divided into 2 hemispheres (Fig. 1).
The left brain hemisphere was coronally cut into 1 cm slices and cryopre-
served (at −80°C). Deep cerebellar nuclei of the left cerebellum were cut
into a 50-μm-thick section and fixed on a piece of cork with Tissue-Tek
O.C.T. Compound (Sakura Finetek GmbH, Staufen, Germany). For
chemical analysis, deep cerebellar nuclei of each sheep were cut in thin
sections of 10-μm thickness with a cryotome and mounted on micro-
scopic glass slides. Before the ablation process, microscopic images
were recorded with a BZ-9000 inverted fluorescence/bright field micro-
scope (Keyence, Osaka, Japan). The right hemisphere of 18 sheep
was formalin fixed (4% buffered formalin), paraffin embedded,
and stored until further analysis. Much care was taken to avoid
cross-contamination between samples, and all instruments were
thoroughly rinsed before the next samples were processed.
Laser Ablation ICP-MS
Matrix-Matched Standards
Spatially resolved determination of gadolinium, copper, iron,
and zinc within the cerebellum thin sections was performed via an
external calibration based on matrix-matched gelatin standards. For
the preparation of aqueous stock solutions, a gadolinium ICP-MS stan-
dard (1000 mg·L−1; Merck KGaA, Darmstadt, Germany) was diluted.
The calibration included 7 concentrations ranging from 0.05 μg·g−1 to
10 μg·g−1. To ensure a good homogeneity, the mixture of gelatin
(10%) and aqueous standard solutions were heated to 45°C and re-
peatedly mixed. The gelatin standards were sectioned with a cryotome
(CryoStar NX70; Thermo Fisher Scientific, Bremen, Germany) to a
thickness of 10 μm to match the thickness of the tissue samples and
ablated using the same conditions for laser ablation and mass spec-
trometry immediately before the analysis of the respective cerebellum
samples to ensure the comparability of the data. For each calibration
standard, 11 lines were recorded over 30 seconds with a laser spot size
of 40 μm and a scan speed of 120 μm·s−1. The first line of each calibra-
tion standard was not included for data analysis due to a larger ablated
area compared with the following 10 lines because of the ablation of
small areas outside the adjusted laser spot size caused by heating pro-
cesses. Validation of the matrix-matched standard concentrations was
performed by bulk analysis. Gelatin standards (50 mg) were digested
by adding 290-μL concentrated HNO3 and diluted to a final volume of
10 mL. Further dilution resulted in a concentration range from 0.25 ng·g−1
to 10 ng·g−1. Rhodium (ICP standard, 1000 mg·L−1, VHG Labs,
Manchester) as internal standard was added before digestion with a final
concentration of 1 ng·g−1. For external calibration, 6 Gd concentrations in
the range from 0.1 ng·g−1 to 20 ng·g−1 with 1 ng·g−1 rhodium were pre-
pared. The resulting concentrations after bulk analysis and the respective
intensities monitored by ICP-MS were applied for linear regression.
Laser Ablation and ICP-MS Parameters
Laser ablation experiments were carried out using a laser abla-
tion system model LSX 213 G2+ with a HelEX Active 2-Volume Cell
(Teledyne CETAC Technologies) and a laser wavelength of 213 nm
coupled via Tygon tubing to a triple quadrupole-based iCAP TQ ICP-MS
(Thermo Fisher Scientific). A laser spot size of 40 μmand a scan speed of
120 μm·s−1 were selected in a line-by-line scan with a distance between
the ablated lines of 0 μm to achieve a reasonable analysis time. To ensure
quantitative ablation of the material, the laser energy was optimized using
a laser frequency of 20 Hz. The laser-generated aerosol was transported
into the ICP-MS by a carrier gas mixture of helium (800 mL·min−1)
and argon (900 mL·min−1) added via a Y-piece directly after the ablation
cell. To convert the transient signal recorded by the ICP-MS instrument
during laser ablation analysis into a 2-dimensional image, an in-house
developed imaging software (MassImager written by R.S., Research
Group Karst, Institute of Inorganic and Analytical Chemistry, Univer-
sity of Münster) was used. The sample introduction system used for
LA-ICP-MS consisted of a quartz injector pipe with an inner diameter
of 3.5 mm. The triple quadrupole-based ICP-MS instrument was used
with oxygen (0.3 mL·min−1) as reaction gas in TQ mode, and gadolin-
ium and phosphoruswere monitored as oxygen reaction products (mass
shift). Sampler and skimmer cones of the ICP interface consisted of
nickel. The following MS conditions were used: 1550 W rf power,
14 L min−1 cooling gas flow, 0.9 L·min−1 nebulizer gas flow, and
0.8 L·min−1 auxiliary gas flow. The isotopes 158Gd+ 16Oand 160Gd+ 16O
weremonitoredwith dwell times of 0.08 second each to achieve optimum
detection limits based on a study by Clases et al20 and Fingerhut et al,21,22
whereas 31P + 16O, 57Fe, 65Cu, and 66Znwere monitoredwith dwell times
of 0.04 second each. For bulk analysis of the gadolinium concentration in
the gelatin standards, the same ICP-MS instrument as for laser ablation
analysis was used with standard liquid sample introduction fed by an
ASX-560 autosampler (Teledyne CETAC Technologies). All analyses
were carried out in KED (He as collision gas, 4.2 mL·min−1) mode with
the following ICP-MS conditions: 1550 W rf power, 14 L·min−1 cooling
gas flow, 1.1 L·min−1 nebulizer gas flow, and 0.8 L·min−1 auxiliary gas
flow. The isotopes 158Gd, 160Gd, and 103Rh were monitored with dwell
times of 0.1 second each.
FIGURE 1. Photographic view on the medial side of the right hemisphere
of a sheep brain during dissection.
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Spatially resolved quantification of gadolinium in the DCN sam-
ples was conducted within thin sections. Because the DCN were not
visible in the microscopic images, the complete thin section had to be
investigated by means of LA-ICP-MS. Therefore, obtaining a reason-
able compromise between analysis time, spatial resolution, and limit
of detection for gadolinium was the main goal of the method develop-
ment. A laser spot size of 40 μm and a scan speed of 120 μm·s−1 turned
out to bemost suitable for the detection of gadolinium, copper, iron, and
zinc within a limited analysis time, nevertheless allowing the dis-
crimination of the DCN from other brain structures. For calibration of
gadolinium, matrix-matched standards based on gelatin were analyzed
as well. Applying these settings, the limit of detection (LOD) and
limit of quantification (LOQ) were calculated based on the 3σ and
10σ criterion, respectively. In TQmode of the ICP-MS instrument with
oxygen as reaction gas, a limit of quantification for 158Gd + 16O of
LOQ = 5.7 ng·g−1 could be achieved (LOD = 1.7 ng·g−1). Finally, it
was assessed by a histopathologist if the DCN could be identified on
the copper, zinc, iron, and gadolinium LA-ICP-MS maps.
For evaluation of the mean gadolinium concentration in the DCN
and the surrounding tissue, an area of the DCN—identified by increased
iron thresholds in this region—was selected. Three regions of interest in-
cluding 500 data points each (approximately 880  880 μm) within the
threshold area were selected for averaging in each thin section within
the DCN. Equally, 3 regions of interest outside the DCN (iron threshold
region) were selected for averaging the gadolinium concentration in the
surrounding tissue.
RESULTS
Visual Assessment of LA-ICP-MS Analysis
A clear colocalization of gadolinium and iron, copper, and zinc
was found in all animals injected with linear GBCAs.
The LA-ICP-MS analysis enabled a clear identification of the 3
DCN for all 18 sheep when iron, copper, and zinc were analyzed. In
contrast, when gadolinium was analyzed, the DCN could exclusively
be identified in those 6 sheep that were injected with linear GBCAs.
A clear colocalization could be found for gadolinium and iron, zinc,
and copper in the LA-ICP-MS when linear GBCAs were injected.
The results after LA-ICP-MS analysis for one representative sample
of each group are shown in Figure 2. The qualitative distribution maps
of iron, copper, and zinc, and the quantitative gadolinium distribution
map are shown in Figure 3, B, C, D, and A, respectively.
Quantitative Analysis
For all animals injected with macrocyclic GBCAs or saline, the
Gd concentration found in either the DCN or the surrounding tissue
was below the limit of quantification (5.7 ng gadolinium/g tissue). In
contrast, mean gadolinium concentrations above the limit of quantifica-
tion between 58 ng gadolinium/g tissue and 167 ng gadolinium/g tissue
were detected for the 6 animals, which were injected with the linear
GBCAs gadodiamide or gadobenate.
Notably, the DCN of all 3 animals who received the linear non-
ionic GBCA gadodiamide showed a higher concentration of gadolinium
(145, 154, 167 ng·g−1) than those of the animals who received theionic
linear GBCA gadobenate (58, 76, 116 ng·g−1). Also, and in agreement
with the visual assessment of the DCN, gadolinium levels for all animals
that were injected with linear GBCAswere higher in the DCN than in the
surrounding area of the DCN. The results for all analyzed animals are
summarized in Table 1 and visualized in Figure 2.
DISCUSSION
In the current study, we found on average 14 times more gado-
linium for gadobenate dimeglumine and 27 times more gadolinium for
gadodiamide in the DCN of sheep than the limit of quantification,
whereas no gadolinium at or above the limit of quantification was found
for the saline group and for all 3 macrocyclic GBCAs. Moreover, we
found a clearly visible accumulation of gadolinium in the DCN as well
as a colocalization of gadolinium with zinc, copper, and iron in the
group of animals that received linear GBCAs, whereas no accumulation
of gadolinium was found when macrocyclic GBCAs were injected.
Our results are in accordance with the majority of published ro-
dent studies23–26 and provide further evidence that the dichotomization
of GBCAs as either linear or macrocyclic is justified. In vitro experi-
ments showed no gadolinium release for macrocyclic GBCAs 14 days
after incubation of human serum at 37 degrees, whereas a gadolinium
release of 20%was shown for the nonionic linear GBCAs and a release
of 2% for the linear ionic GBCAs.27 Based on this in vitro study27 and
animal studies,23–25,28,29 the hypothesis has been developed that mac-
rocyclic GBCAs remain in their chelated form and are washed out
from the brain over time through the glymphatic system, whereas
linear GBCAs partly dechelate in the brain in metal-rich areas by
transmetalation.18,30 A recent study by Deike-Hofmann31 showed that
an SI increase can be found first in the choroid plexus and subsequently
in the CSF, suggesting a pathway of the intravenously injected GBCAs
through the glymphatic system of the brain. It can be hypothesized
that the “dechelation rate” of GBCAs on this pathway through the
glymphatic system is determined by (1) the stability of the injected
GBCA, (2) the amount of the injected GBCA, (3) the duration of
the injected GBCA within the glymphatic system, and (4) the con-
centration and availability of potential transmetalation partners.
The colocalization of gadolinium in the DCN with zinc, iron,
and copper that was found in the current study might be explained by
the increased transmetalation of the GBCAs caused by an increased
supply of potential transmetalation partners in the metal-rich area of
the DCN. The theory of a partial transmetalation of linear GBCAs is
in the current study also supported by the decreased amount of gadolin-
ium found in the surrounding area that contain less metal compared
with the DCN (Table 1, Fig. 2). The absence of any statistically signif-
icant gadolinium accumulation in the DCN for macrocyclic GBCAs is,
moreover, in agreement with the theory that macrocyclic GBCAs do not
dechelate in vivo to a significant degree and are excreted over time
through the glymphatic system.23,24
FIGURE 2. Gadolinium concentration in the DCN (light gray) and in
the surrounding area (dark gray) for all GBCAs. The detection limit of
gadolinium was not reached for any of the macrocyclic GBCAs.
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It is important to note that the excretion process of GBCAs through
the glymphatic system requires time—an almost total washout was found
in rodents 5 months after injection of a very high amount of macrocyclic
GBCAs in the study by Robert et al.24 Hence, studies that determine the
total gadolinium content at a time point when the washout process is still
in progress will result in a mixture of the intact gadolinium chelate that is
in thewashout process and the potentially long-standing gadolinium depo-
sition of released gadolinium that is bound to different partners.24,26
The different duration between gadolinium injection and the an-
imal euthanization is most likely also the reason for varying results of a
FIGURE 3. Representative results for the LA-ICP-MS analyses of cryo cerebellum samples of sheep treated either with gadodiamide, gadobenate,
gadobutrol, gadoteridol, gadoterate, or saline solution. The quantitative distributionmap of gadolinium (158Gd + 16O) for each sample is shown in (A),
and the qualitative distribution maps of iron (57Fe), copper (65Cu), and zinc (66Zn) are depicted in (B, C, D). LA-ICP-MS analyses were performed with a
laser spot size of 40 μm and a limit of quantification at 5.7 ng/g (LOQ). The deep cerebellar nuclei are marked by dotted lines. A clear colocalization of
gadolinium displays for iron, copper, and zinc in all animals. In contrast, an accumulation for gadolinium could only be found for the linear GBCAs
gadodiamide and gadobenate, whereas no accumulation was found for the macrocyclic GBCAs.
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rodent study by McDonald et al32 that showed only moderate differ-
ences between gadolinium retention of linear GBCAs (gadodiamide:
median, 6.9; gadobenate: median, 4.7 μg/g of brain tissue) and the mac-
rocyclic GBCA gadobutrol (median, 1.6 μg/g of brain tissue). In the
McDonald study, the animals were euthanized 9 days after injection,
which might not be a sufficient period to allow a clearance of the mac-
rocyclic GBCA gadobutrolfrom the glymphatic system. Notably, no
gadolinium was found 9 days after injection in the McDonald study
for the macrocyclic GBCA gadoteridol, which might—at least for the
analyzed rodent model—support the hypothesis of different washout
kinetics for macrocyclic GBCAs. Finally, it needs to be noted that
McDonald et al injected 50 times higher gadolinium dosages (20 injec-
tions of 2.5 mmol/kg) than the current study (single injection of
0.1 mmol/kg), which might have influenced the washout process.
Generally, gadolinium in any chenical form (with higher relaxivities
if bound to macromolecules) first becomes visible inMRI if a threshold of
approximately 1 μg/g of tissue is exceeded. Hence, even for the animals
injected with linear GBCAs (highest amount for gadodiamide: average,
155.33 ng/kg tissue), we would have most likely not been able to show
any signal intensity changes in MRI. For humans, it has been shown that
hyperintensities in the DN finally become visible after 6 injections of
linear GBCAs (0.1 mmol/kg body weight linear).6,12 Interestingly, the
level of detection for the visibility of hyperintensities in the DN of
1 μg would have been reached after approximately 6 injections of
0.1 mmol in the current sheep model (6 times 155.53 ng ~ 1 μg), which
might support the comparability of the sheep model and the conditions
in human beings. Importantly, the results of our study can explain the
fact that a signal intensity increase on T1-weighted MRI scans could
be found in the majority of the published studies when linear GBCAs
were injected,2,11,12,14–16,33whereas no effect was found in the majority
of studies that investigated macrocyclic GBCAs.6,8–10,13
Because we did not find any gadolinium accumulation in the
DCN for macrocyclic GBCAs, it is, from a methodological point of
view, impossible that any SI increase on T1-weighted MRI scans is
caused by macrocyclic GBCAs in the current experimental setup.
However, it cannot be excluded that gadolinium accumulation in the
DCN appears finally when higher dosages of macrocyclic GBCAs are
applied. Considering the strong differences of gadolinium deposition be-
tween linear and macrocyclic GBCAs found in the current study, and the
fact that hyperintensities after serial administrations of linear GBCAs also
first become apparent after approximately 6 injections,11 it seems highly
unlikely that the administration of macrocyclic GBCAs might ever reach
the level that a visible signal intensity increase in the DCN can be caused
in a clinical setting.
Our study is different to the majority of published animal studies
assessing gadolinium retention in 2 aspects. First, we used a large ani-
mal model, whereas the previously published studies primarily focused
on rodent models. Second, we investigate gadolinium retention after the
injection of a single clinical dosage of GBCAs—with the same concen-
tration (0.1 mmol/kg) that is used in patients in clinical practice.
The reason for using a sheep model instead of the established ro-
dent model is that the sheep anatomy ismuchmore similar to the human
anatomy and it has recently been correctly emphasized that the rodent
model might not be optimal for the investigation of gadolinium deposi-
tion.34Moreover, this approach enabled us to assess the gadolinium de-
position exclusively in the DCN because this area is far larger in sheep
compared with rodents, and a precise delineation of the DCN could be
guaranteed. In contrast, the previously published studies on rodent
brains determined the total concentration of gadolinium in the cerebel-
lum, which might have included gadolinium in the glymphatic system
during the washout process and hence not adequately reflect gadolin-
ium in the cerebellar nuclei.
We assessed gadolinium deposition after a single injection of
GBCAs in the current study to simulate the clinical conditions under
which the majority of GBCA injections are performed in clinical prac-
tice. The study was conducted in a prospective approach as an add-on
study to an ongoing study that aimed to determine the influence of
the food composition on tooth abrasion. Therefore, the study design
was restricted, and the ability to increase the applied amount of GBCAs
was limited. Although the study design followed the 3R requirements
(replace, reduce, refine) and was in accordance with the ethical obliga-
tion to maximize knowledge that can be obtained from animal experi-
ments, it did not allow us to prolong the time between injection and
euthanization of the sheep. Generally, it is favorable to euthanize the an-
imals a long period after the last injection of GBCAs to determine long-
term gadolinium deposition. The selected period of 10 weeks was the
longest interval that could be achieved under the conditions of the ongo-
ing study. However, the fact that no significant difference was found be-
tween the gadolinium amount retained for macrocyclic GBCAs and the
control group supports the hypothesis that the washout process of mac-
rocyclic GBCAs from the glymphatic system was almost completed.31
Limitations of our study must be acknowledged. First of all, the
low amount of injected gadolinium unfortunately impeded a speciation
analysis of the retained gadolinium.
Moreover, an obvious limitation is the fact that all animals were
euthanized after 10 weeks, and hence we cannot conclude if the found
gadolinium for the linear GBCAswill remain in the brain or be excreted
after a longer period. However, given the proposed pathomechanism
of a partial dechelation and the pharmakokinetic modeling performed
in the study by Robert et al24 and Jost et al,23 it seems likely that at
least part of the gadolinium will be trapped resulting in long-term
gadolinium deposition.
As mentioned previously, a further limitation of our study is that
we only examined a single dose of GBCAs, andwe hence cannot exclude
that traces of gadolinium from linear or macrocyclic GBCAs can be
found when higher dosages are applied. However, we wanted to focus
TABLE 1. Mean Gadolinium Concentration Within the DCN and in





Sheep Number Within DCN Surrounding of DCN Administration
1 <LOQ, 3 <LOQ, 2 Gadobutrol
6 <LOQ, 3 <LOQ, 2 Gadobutrol
4 <LOQ, 2 <LOQ, 2 Gadobutrol
3 <LOQ, 4 <LOQ, 3 Gadoteridol
7 <LOQ, 3 <LOQ, 2 Gadoteridol
5 <LOQ, 4 <LOQ, 2 Gadoteridol
9 <LOQ, 2 <LOQ, 2 Gadoterate
11 <LOQ, 2 <LOQ, 2 Gadoterate
12 <LOQ, 2 <LOQ, 2 Gadoterate
8 116 69 Gadobenate
15 76 32 Gadobenate
2 58 28 Gadobenate
13 167 73 Gadodiamide
14 145 43 Gadodiamide
18 154 34 Gadodiamide
10 <LOD (1) <LOD (1) Saline solution
16 <LOQ, 3 <LOQ, 2 Saline solution
17 <LOQ, 2 <LOQ, 3 Saline solution
LOD = 1.7 ng·g−1; LOQ = 5.7 ng·g−1.
DCN indicates deep cerebellar nuclei; LA-ICP-MS, laser ablation-inductively
coupled plasma-mass spectrometry; GBCA, gadolinium-based contrast agent;
LOQ, limit of quantification; LOD, limit of detection.
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on the most relevant clinical situation, which is the injection of a single
dosage of GBCAs. The results of our study might reassure patients
that there is no measurable gadolinium in the DCN compared with
the background level of gadolinium 10 weeks after injection of a single
dose of macrocyclic GBCAs in a large animal model.
To summarize, the current study provides evidence from a large
animal model that linear GBCAs leave traces of gadolinium within
the DCN, while there was no significant difference of gadolinium
concentrations between all 3 marketed macrocyclic GBCAs and
the control group. Moreover, the specific accumulation of gadolin-
ium from linear GBCAs as well as the colocalization with different
metals in the DCN support the hypothesis that a partial dechelation
of the less stable linear GBCAs is the cause of gadolinium deposition
as well as of the signal intensity increase in the DCN on T1-weighted
MRI scans caused by linear GBCAs.
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